By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Genzyme Corporation 

500 Kendall Street

Cambridge  Massachusetts  02142  U.S.A.
Phone: 617-252-7500 Fax: 617-252-7600


About Genzyme

Genzyme is committed to discovering and delivering transformative therapies for patients with rare and special unmet medical needs, providing hope where there was none before.

Genzyme has pioneered the development and delivery of transformative therapies for over 30 years. Founded in 1981 in Boston, Massachusetts, Genzyme evolved from a tiny start-up with just a handful of employees to one of the world's leading biotech companies. Acquired by Sanofi in 2011, Genzyme now benefits from the reach and resources of one of the world’s largest pharmaceutical companies, with a shared commitment to improving the lives of patients.

Genzyme has long been known for our expertise in the class of rare genetic diseases known as lysosomal storage disorders (LSDs). LSDs remain the heart of our company today, but we have also expanded – through both in-house development and strategic acquisitions and partnerships – to other disease areas such as thyroid cancer and multiple sclerosis.

Learn more at

Follow our jobs on Twitter

Follow us on LinkedIn

About Sanofi

Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, rare diseases, consumer healthcare, emerging markets, and animal health. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Key Statistics

Ownership: Subsidiary

Web Site: Sanofi Genzyme
Symbol: SNY



Medtronic  Cardiac Cell Therapy

Cambridge Antibody Technology (CAT)  Antibodies against TGF-ß

Dyax  Hereditary Angioedema


Company News
Rhythm Appoints Head Of Sanofi Genzyme (SNY), Dr. David Meeker, As Chairman Of Board Of Directors 4/11/2017 9:12:09 AM
More Than 30 Presentations Of New Investigational Data From Sanofi Genzyme (SNY)’s Multiple Sclerosis Franchise To Be Featured AtAAN 4/11/2017 8:21:11 AM
Sanofi Genzyme (SNY) Exec Exits to Become CMO of Flexion (FLXN)—Sanofi (SNY)'s Rumored Buyout Target 4/7/2017 5:58:25 AM
Sanofi Genzyme (SNY) Head to Leave After 23 Years on the Job, Replacement Named 4/5/2017 7:36:21 AM
Sanofi Genzyme (SNY) Extends Its Multiple Myeloma Journey Partners Program To Cities Nationwide To Help Improve Patient Outcomes Through Peer-To-Peer Education 3/22/2017 10:19:54 AM
What’s That Thing On Top Of The Sanofi Genzyme (SNY) Building Anyway? 3/14/2017 7:29:09 AM
Sanofi Genzyme (SNY) Release: Kevzara (Sarilumab) Now Available In Canada For The Treatment Of Adult Patients With Moderately To Severely Active Rheumatoid Arthritis 2/28/2017 8:11:07 AM
Sanofi Genzyme (SNY) Recognizes Rare Disease Day 2017 With Programs Of Events Around The World 2/28/2017 6:29:45 AM
Sanofi Genzyme (SNY) Announces Start Of Phase III Study Of Isatuximab For Relapsed And Refractory Multiple Myeloma 12/5/2016 11:16:30 AM
Sanofi Genzyme (SNY) Release: Nova Scotia Includes LEMTRADA (Alemtuzumab) On Provincial Drug Program For Eligible Patients 12/2/2016 11:48:02 AM